Skip to main content
. Author manuscript; available in PMC: 2012 Nov 22.
Published in final edited form as: J Am Coll Cardiol. 2011 Nov 22;58(22):2332–2339. doi: 10.1016/j.jacc.2011.07.048

Figure 2. Western blot analysis of protein levels.

Figure 2

All results are corrected for the GAPDH level. (A) The total c-Src protein level was 1.47-fold higher in ACE8/8 mice than in wild-type mice (P < 0.05), and the phospho-(Tyr416) c-Src protein level was 2.6-fold higher in ACE8/8 mice than in control mice (P < 0.05). The Cx43 level was reduced in ACE8/8 mouse hearts to 36% of the level in wild-type mouse hearts (P < 0.005 (n=6 for all groups). (B) PP1 treatment: Four weeks of intraperitoneal injection of PP1 in ACE8/8 mice decreased the total c-Src protein level to 58% of that in untreated ACE8/8 mice (P < 0.05) and reduced the phospho-(Tyr 416) c-Src level to 75% of that in untreated ACE8/8 mice (P < 0.05). More importantly, PP1 treatment resulted in a 2.1-fold increase in the Cx43 level in ACE8/8 mice and increased the level of Cx43 to 68% of its normal level in wild-type mice (n=6 for all groups). (C) The ACE level was increased 11.9-fold in ACE8/8 mice compared to the control animals (P < 0.005). Treatment with PP1 did not change the cardiac ACE level in ACE8/8 mice (P = NS). Treatment of wild-type animals with PP1 did not change significantly the total level of Cx43 (P = NS) (n=6 for all groups).